Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva Tablet Approved in Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical Co. announced Oct. 22 that the Japanese Ministry of Health Labour and Welfare has granted approval to Tarceva. The drug has been approved for use in patients with certain types of lung-cancer that can be aggravated by chemotherapy. The Ministry of Health's decision comes on the heels of several successful clinical trials which revealed Tarceva was safe and effective and had a low incidence of side effects. The drug has been approved for marketing in doses of 25 mg, 100 mg, and 150 mg. (Click here for more
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.